ID

21092

Description

Blood Sugar Response to Commercial Nutritional Supplements in Patients With Type 2 Diabetes; ODM derived from: https://clinicaltrials.gov/show/NCT00822367

Link

https://clinicaltrials.gov/show/NCT00822367

Keywords

  1. 4/10/17 4/10/17 -
Uploaded on

April 10, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Diabetes Mellitus Type 2 NCT00822367

Eligibility Diabetes Mellitus Type 2 NCT00822367

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
ages 18-75 years
Description

Age

Data type

boolean

Alias
UMLS CUI [1]
C0001779
type-2 diabetes mellitus for over 3 months
Description

Diabetes mellitus type 2

Data type

boolean

Alias
UMLS CUI [1]
C0011860
a1c of 7.0 - 10.0% within the past 3 months
Description

HbA1c

Data type

boolean

Alias
UMLS CUI [1]
C0019018
controlled with diet /exercise and/or on oral anti-diabetic agents which are non-insulin secretatgogues, i.e. metformin and/or pioglitazone
Description

Diabetes mellitus therapy

Data type

boolean

Alias
UMLS CUI [1]
C0948092
able to give informed consent
Description

Informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
expected to be in the dc metropolitan for the duration of the study
Description

Residency

Data type

boolean

Alias
UMLS CUI [1]
C0035182
fasting blood glucose between 70 and 250 mg/dl
Description

Fasting blood glucose measurement

Data type

boolean

Alias
UMLS CUI [1]
C0428568
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (symlin), glp-1 analogs (byetta), insulin, or alpha-glycosidase inhibitors
Description

Diabetes mellitus therapy: Pharmacotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C0948092
UMLS CUI [1,2]
C0013216
a1c under 7.0% or over 10.0%
Description

HbA1c

Data type

boolean

Alias
UMLS CUI [1]
C0019018
fasting blood glucose < 70 or > 250 mg/d
Description

Fasting blood glucose measurement

Data type

boolean

Alias
UMLS CUI [1]
C0428568
gastrointestinal disorders affecting digestion and absorption of nutrients such as lactose intolerance, chronic diarrhea, pancreatic insufficiency.
Description

Gastrointestinal disorders

Data type

boolean

Alias
UMLS CUI [1]
C0017178
clinical history of documented gastroperesis.
Description

Gastroparesis

Data type

boolean

Alias
UMLS CUI [1]
C0152020
patients on hemodialysis or peritoneal dialysis
Description

Hemodialysis or peritoneal dialysis

Data type

boolean

Alias
UMLS CUI [1]
C0019004
UMLS CUI [2]
C0031139
pregnancy
Description

Pregnancy

Data type

boolean

Alias
UMLS CUI [1]
C0032961
inability to read and/or speak english
Description

Language ability

Data type

boolean

Alias
UMLS CUI [1]
C1145677

Similar models

Eligibility Diabetes Mellitus Type 2 NCT00822367

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
ages 18-75 years
boolean
C0001779 (UMLS CUI [1])
Diabetes mellitus type 2
Item
type-2 diabetes mellitus for over 3 months
boolean
C0011860 (UMLS CUI [1])
HbA1c
Item
a1c of 7.0 - 10.0% within the past 3 months
boolean
C0019018 (UMLS CUI [1])
Diabetes mellitus therapy
Item
controlled with diet /exercise and/or on oral anti-diabetic agents which are non-insulin secretatgogues, i.e. metformin and/or pioglitazone
boolean
C0948092 (UMLS CUI [1])
Informed consent
Item
able to give informed consent
boolean
C0021430 (UMLS CUI [1])
Residency
Item
expected to be in the dc metropolitan for the duration of the study
boolean
C0035182 (UMLS CUI [1])
Fasting blood glucose measurement
Item
fasting blood glucose between 70 and 250 mg/dl
boolean
C0428568 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Diabetes mellitus therapy: Pharmacotherapy
Item
patients with type 2 diabetes mellitus treated with insulin secretagogues (sulfonylurea and non-sulfonylurea), pramlintide (symlin), glp-1 analogs (byetta), insulin, or alpha-glycosidase inhibitors
boolean
C0948092 (UMLS CUI [1,1])
C0013216 (UMLS CUI [1,2])
HbA1c
Item
a1c under 7.0% or over 10.0%
boolean
C0019018 (UMLS CUI [1])
Fasting blood glucose measurement
Item
fasting blood glucose < 70 or > 250 mg/d
boolean
C0428568 (UMLS CUI [1])
Gastrointestinal disorders
Item
gastrointestinal disorders affecting digestion and absorption of nutrients such as lactose intolerance, chronic diarrhea, pancreatic insufficiency.
boolean
C0017178 (UMLS CUI [1])
Gastroparesis
Item
clinical history of documented gastroperesis.
boolean
C0152020 (UMLS CUI [1])
Hemodialysis or peritoneal dialysis
Item
patients on hemodialysis or peritoneal dialysis
boolean
C0019004 (UMLS CUI [1])
C0031139 (UMLS CUI [2])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Language ability
Item
inability to read and/or speak english
boolean
C1145677 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial